[go: up one dir, main page]

MX2018000951A - Una formulacion lista para usar, para la inyeccion de liposomas de sulfato de vincristina. - Google Patents

Una formulacion lista para usar, para la inyeccion de liposomas de sulfato de vincristina.

Info

Publication number
MX2018000951A
MX2018000951A MX2018000951A MX2018000951A MX2018000951A MX 2018000951 A MX2018000951 A MX 2018000951A MX 2018000951 A MX2018000951 A MX 2018000951A MX 2018000951 A MX2018000951 A MX 2018000951A MX 2018000951 A MX2018000951 A MX 2018000951A
Authority
MX
Mexico
Prior art keywords
ready
vincristine sulfate
use formulation
liposome injection
sulfate liposome
Prior art date
Application number
MX2018000951A
Other languages
English (en)
Other versions
MX380095B (es
Inventor
T Monte William
Malcolm Abra Robert
Luo Bing
Zhang Yuanpeng
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of MX2018000951A publication Critical patent/MX2018000951A/es
Publication of MX380095B publication Critical patent/MX380095B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen diversas composiciones que comprenden formulaciones neoplásticas y sus métodos de uso.
MX2018000951A 2015-07-22 2016-07-22 Una formulación lista para usar, para la inyección de liposomas de sulfato de vincristina. MX380095B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195711P 2015-07-22 2015-07-22
PCT/US2016/043622 WO2017015584A1 (en) 2015-07-22 2016-07-22 A ready-to-use formulation for vincristine sulfate liposome injection

Publications (2)

Publication Number Publication Date
MX2018000951A true MX2018000951A (es) 2018-06-07
MX380095B MX380095B (es) 2025-03-11

Family

ID=57835279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000951A MX380095B (es) 2015-07-22 2016-07-22 Una formulación lista para usar, para la inyección de liposomas de sulfato de vincristina.

Country Status (14)

Country Link
US (1) US11559486B2 (es)
EP (1) EP3324969B1 (es)
JP (1) JP6850788B2 (es)
KR (2) KR102384126B1 (es)
CN (1) CN107864624B (es)
AU (1) AU2016206387B2 (es)
CA (1) CA2992724C (es)
ES (1) ES2808938T3 (es)
IL (1) IL257068B (es)
MX (1) MX380095B (es)
RU (1) RU2676762C1 (es)
TW (1) TWI678213B (es)
WO (1) WO2017015584A1 (es)
ZA (1) ZA201800391B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932718A (en) 1957-06-25 1960-04-12 Thomas D Kinney Test tube warmer
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
JPH0244450B2 (ja) * 1982-07-19 1990-10-04 Lilly Co Eli Binka*arukaroidoseizai
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
CA1260393A (en) 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5622713A (en) 1985-09-17 1997-04-22 The Regents Of The University Of California Method of detoxifying animal suffering from overdose
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5755788A (en) 1987-02-19 1998-05-26 Rutgers, The State University Prosthesis and implants having liposomes bound thereto and methods of preparation
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US5262168A (en) 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US4952408A (en) 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
JPH04505616A (ja) 1989-05-15 1992-10-01 ザ　リポソーム　カンパニー，インコーポレイテッド プロトン勾配によるリポソームへの薬剤の蓄積
WO1991004019A1 (en) 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
HU204995B (en) 1989-11-07 1992-03-30 Richter Gedeon Vegyeszet Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
ATE194767T1 (de) 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
GB9304745D0 (en) 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
IL115099A (en) 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE69634084T2 (de) 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0949906A4 (en) 1996-10-22 2004-11-24 Hermes Biosciences Inc LIPOSOMES LOADED WITH ACTIVE SUBSTANCE AND THEIR PRODUCTION METHOD
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
NZ336381A (en) 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
NZ503293A (en) 1997-09-16 2002-09-27 Nexstar Pharmaceuticals Inc Liposomal camptothecin formulations also comprising at least one phospholipid
US6740335B1 (en) 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
CA2346879A1 (en) 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
DE19913640A1 (de) * 1999-03-25 2000-09-28 Taiwan Liposome Co Zusammensetzungen und Verfahren zur Vorbeugung der Aggregation von Liposomen
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AU777572B2 (en) * 1999-04-01 2004-10-21 Board Of Regents, The University Of Texas System Compositions and methods for treating lymphoma
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7244450B2 (en) 1999-04-01 2007-07-17 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6500911B1 (en) 1999-05-20 2002-12-31 Daicel Chemical Industries, Ltd. Polyester diol and derived polyurethane and acrylic copolymer
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
AU7038501A (en) 2000-06-30 2002-01-14 Inex Pharmaceuticals Corp Liposomal antineoplastic drugs and uses thereof
IL155291A0 (en) 2000-10-16 2003-11-23 Neopharm Inc Liposomal formulation of mitoxantrone
US6825206B1 (en) 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
WO2002046372A1 (en) 2000-12-08 2002-06-13 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
EP1443900B1 (en) 2001-11-13 2012-05-23 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
US6627614B1 (en) 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
WO2004035032A2 (en) 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20040156888A1 (en) * 2002-11-26 2004-08-12 Jensen Gerard M. Liposomal formulations
JP4245384B2 (ja) 2003-03-18 2009-03-25 株式会社ヤクルト本社 カンプトテシン類含有医薬組成物
EP1643972A4 (en) 2003-06-27 2010-01-20 Smithkline Beecham Corp STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD
US20050129750A1 (en) 2003-12-15 2005-06-16 Yu-Fang Hu Process for producing liposome suspension and product containing liposome suspension produced thereby
RU2424792C2 (ru) 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
CA2566559C (en) 2004-05-17 2014-05-06 Inex Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
US7449196B2 (en) 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
EP1781255B1 (en) 2004-08-10 2012-02-15 Talon Therapeutics, Inc. Compositions and methods for treating leukemia
AU2005304914B2 (en) 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
KR100793819B1 (ko) 2006-06-16 2008-01-10 주식회사 펩트론 히트 블록 어셈블리 및 그를 이용한 유기 화합물 합성 반응장치
US8563907B2 (en) 2008-02-26 2013-10-22 Mallinckrodt Llc Radiopharmaceutical heater
US8790691B2 (en) * 2008-05-23 2014-07-29 The University Of British Columbia Modified drugs for use in liposomal nanoparticles
SI2404608T1 (sl) 2009-03-04 2015-06-30 Otsuka Pharmaceutical Co., Ltd. Holestanolni derivat za kombinirano uporabo
US11357728B2 (en) * 2009-10-26 2022-06-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
CN102596178B (zh) * 2009-10-26 2014-12-03 石药集团中奇制药技术（石家庄）有限公司 具有磺丁基醚环糊精盐内水相的脂质体
EP2531175A2 (en) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
JP2013126953A (ja) * 2010-03-31 2013-06-27 Terumo Corp リポソーム製剤の製造方法
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
JP2013063923A (ja) * 2011-09-16 2013-04-11 Terumo Corp リポソーム製剤の製造方法
CA2864469C (en) * 2012-02-17 2020-07-07 Celsion Corporation Thermosensitive nanoparticle formulations and method of making the same
JP2014081887A (ja) * 2012-10-18 2014-05-08 Virtalex Consulting Inc セキュアシングルサインオン方式およびプログラム
EP3470061A1 (en) * 2012-11-20 2019-04-17 Spectrum Pharmaceuticals, Inc. Improved method for the preparation of a dosage of liposome encapsulated vincristine for therapeutic use
WO2014113167A1 (en) * 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
CN103520159B (zh) * 2013-09-29 2015-06-17 邱利焱 奎宁类药物和长春新碱类药物共载脂质体及其制备方法
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物

Also Published As

Publication number Publication date
BR112018001145A2 (pt) 2018-09-11
JP2018521080A (ja) 2018-08-02
CA2992724C (en) 2023-08-15
KR20180122050A (ko) 2018-11-09
TWI678213B (zh) 2019-12-01
US20180153805A1 (en) 2018-06-07
RU2676762C1 (ru) 2019-01-11
TW201717913A (zh) 2017-06-01
JP6850788B2 (ja) 2021-03-31
IL257068A (en) 2018-02-28
AU2016206387A1 (en) 2017-02-09
AU2016206387B2 (en) 2017-05-25
US11559486B2 (en) 2023-01-24
KR20180016612A (ko) 2018-02-14
EP3324969A4 (en) 2019-05-01
CN107864624A (zh) 2018-03-30
HK1250477A1 (zh) 2018-12-21
KR101916835B1 (ko) 2018-11-08
CA2992724A1 (en) 2017-01-26
ZA201800391B (en) 2018-12-19
ES2808938T3 (es) 2021-03-02
HK1248563A1 (zh) 2018-10-19
EP3324969B1 (en) 2020-07-01
KR102384126B1 (ko) 2022-04-06
EP3324969A1 (en) 2018-05-30
IL257068B (en) 2021-07-29
MX380095B (es) 2025-03-11
WO2017015584A1 (en) 2017-01-26
CN107864624B (zh) 2021-05-25

Similar Documents

Publication Publication Date Title
DOP2020000021A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
CL2019000992A1 (es) Conjugados de pirrolobenzodiazepina.
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
MX388018B (es) Anticuerpos anti-pd1 y métodos de uso.
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CR20170573A (es) Lactamas bicíclicas y métodos de uso de las mismas
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
CR20150462A (es) Inhibidores de erk y sus usos
MX2020003693A (es) Dispositivos de entrega intranasales.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
DOP2017000298A (es) Reguladores de nrf2
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
UY36330A (es) Compuestos inhibidores de quinasa de unión a tank
BR112021011124A2 (pt) Anelossomos e métodos de uso
CO7141409A2 (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
BR112017027721A2 (pt) formulação de alta concentração
ECSP17057131A (es) Desacetoxitubulisina h y análogos de esta
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
MX2017015315A (es) Granos de gluten reducido y composiciones de los mismos.
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
BR112017002090A2 (pt) formulação de fator viii